Royalty Pharma plc (RPRX) FY2025 Annual P&L / Income Statement

Royalty Pharma plc (RPRX) FY2025 Annual P&L / Income Statement

Income statement for 2025-01-01 through 2025-12-31. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total income and other revenues

2,378,193,000 US dollars

Total operating expense, net

818,675,000 US dollars

Operating income

1,559,518,000 US dollars

Total other expense/(income), net

negative 235,326,000 US dollars

Consolidated net income before tax

1,324,192,000 US dollars

Income tax expense

0 US dollars

Consolidated net income

1,324,192,000 US dollars

Income from financial royalty assets

2,261,152,000 US dollars

Other royalty income and revenues

117,041,000 US dollars

Provision for changes in expected cash flows from financial royalty assets

negative 295,838,000 US dollars

Provision for credit losses on unfunded commitments

89,032,000 US dollars

Research and development funding expense

452,000,000 US dollars

General and administrative expenses (includes $290,890, $3,224, and $3,302 of share-based compensation expense for the years ended December 31, 2025, 2024 and 2023, respectively; see Note 4)

573,481,000 US dollars

Chart connections

• Revenue minus operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
• Of which attributable to Royalty Pharma plc: $770.95 M; to noncontrolling interests: $553.25 M.